

Unique Solutions to the Challenges of ADC Development

Webinar Date/Time

Tuesday, December 9th from 10 - 11am EST

Presenter(s)

Marc Bruder, DVM, Cert. Tox. Path., Biologics Solutions Director,
Covance, Inc.

FULL ABSTRACT

Most antibody-drug-conjugate (ADC) indications are in the oncology therapeutic area but other therapeutic areas are considering ADC use as well (e.g., immunomodulation). The development of a complex molecule such as an ADC involves multiple challenges starting at the manufacturing stage. Later, establishing the safety aspects of the compound involves selecting nonclinical species where the ADC presents similar affinity, potency and activity as in the human species, and determining multiple factors of toxicity linked to the antibody properties, the stability of the ADC, its drug-antibody ratio and the nature of the cytotoxic drug chosen, to name a few. Some unforeseen toxicological events during nonclinical safety assessment may drive the need for mechanistic studies or assays to measure potential toxicity factors such as internalization speed or receptor density variation between organs.

Learn more about our drug development solutions at www.covance.com/biologics

Covance is an independently held company with headquarters in Princeton, New Jersey, USA.
Covance is the marketing name for Covance Inc. and its subsidiaries around the world.

The Americas + 1.888.COVANCE + 1.609.452.4440
Europe / Africa + 00.800.2682.2682 Asia Pacific + 800.6568.3000

© Copyright 2014 Covance Inc.

COVANCE
SOLUTIONS MADE REAL™